Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
February 25, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant...
BioAegis Therapeutics Expands Phase 1b/2a Community-Acquired Pneumonia Study to the Republic of Georgia —Successfully Completes Second of Four Dosing Cohorts
February 07, 2019 09:17 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that patient enrollment is underway in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...
BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study
February 01, 2019 10:53 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced the publication of a paper in Clinical Infectious Disease—a journal of the Infectious Disease Society of...
New Genomic Technology Advances Fight Against Global Health Threat of Antibiotic Resistance
December 06, 2018 09:14 ET
|
Phase Genomics
SEATTLE, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Phase Genomics, the leader in proximity-ligation genome assembly technology released an antimicrobial resistance (AMR) study led by researchers from the...
SpeeDx Receives CE-IVD Mark for ResistancePlus® GC Gonorrhea Test
December 06, 2018 03:30 ET
|
SpeeDx Pty Ltd
SYDNEY, Australia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted...
Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam)
November 27, 2018 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
HP Accelerates 3D Printing Mass Production with New Customers, Applications, and Partners
November 13, 2018 03:00 ET
|
HP Inc.
Announces new customers RecTech 3D and GE Transportation; New applications by BMW, Volkswagen, and others; First HP Jet Fusion 3D 300 / 500 Series customers; Collaborates with Autodesk on...
Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
November 12, 2018 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week Preclinical Data on New...
Streetwise Reports Examines Why This Biotech, Whose Discovery Could End Routine Antibiotic Use in Livestock, Is the Pick of Three Fund Managers
October 31, 2018 07:00 ET
|
Streetwise Reports Llc
SAN FRANCISCO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (VIV:TSX.V), a biotech company focused on science-based, natural health products for livestock, companion animals and humans, is making...
Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP
October 29, 2018 08:00 ET
|
Melinta Therapeutics
– Met primary endpoint of Early Clinical Response at 96 hours after the first dose – – Supplemental NDA expected to be filed with FDA in 1H 2019 – – Baxdela currently FDA approved for treatment of...